**Supplemental Table 1. Baseline Patient Characteristics (Safety Population)**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Placebo/ChEI**  **n=335** | **Memantine ER/ChEI**  **n=341** |
| **Age, y, mean (SD)** | 76.8 (7.8) | 76.2 (8.4) |
| **Women, n (%)** | 243 (72.5) | 244 (71.6) |
| **White, n (%)** | 312 (93.1) | 324 (95.0) |
| **MMSE score, mean (SD)** | 10.6 (2.9) | 10.9 (2.9) |
| **MMSE range** | 3–15 | 3–17 |
| **Concomitant ChEI** | | |
| **Donepezil, n (%)** | 228 (68.1) | 236 (69.2) |
| **Galantamine, n (%)** | 68 (20.3) | 72 (21.1) |
| **Rivastigmine, n (%)** | 41 (12.2) | 32 (9.4) |

ChEI, cholinesterase inhibitor; Memantine ER, extended-release memantine 28 mg/day; MMSE, Mini-Mental State Examination; SD, standard deviation